All News
Links:
Dr. John Cush RheumNow ( View Tweet)
Treatments Differ Across Centers in Systemic JIA
Significant variations were seen across hospitals in the treatment of children admitted with new-onset systemic juvenile idiopathic arthritis (JIA), despite increasing evidence of the efficacy of biologics and the hazards of extended glucocorticoid exposure, a retrospective cohort study found.
Read Article
Do NSAIDs Increase Cardiovascular Risk in Osteoarthritis?
A longitudinal study of administrative data from British Columbia shows that nonsteroidal antiinflammatory drugs (NSAIDs) use increases the risk of cardiovascular disease (CVD) among osteoarthritis (OA) patients.
Read Article
In Lupus, Older Age and Male Sex Raise Cancer Risk
Among patients with systemic lupus erythematosus (SLE), cancer risks overall were associated with older age at diagnosis and male sex, and lung cancer specifically was related to smoking, analysis of data from a large multicenter cohort found.
Read Article
Update on Polymyalgia Rheumatica and Giant Cell Arteritis
JAMA has published a clinical update of recent studies on GCA. While PET/CT scanning are novel means of demonstrating activity, they have not changed the diagnostic approach to GCA or PMR and although there are no new proven treatment strategies for PMR beyond glucocorticoids, the FDA has approved tocilizumab as a first-line glucocorticoid-sparing agent.
Read Article
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Links:
Links:
Links:
Dr. John Cush RheumNow ( View Tweet)
Selective Biologic Responses in Seropositive RA
The Journal of Rheuatology reports a pooled analysis of patients from 16 observational RA registries that examined the association between seropositivity (RF or ACPA) with biologic DMARDs responses; they showed better clinical responses when seropositive RA patients receive abatacept (ABA) o
Read Article
RheumNow Podcast – The Bad News That’s Fit to Print (8.21.20)
Dr Jack Cush reviews the news and journal reports from the past week on RheumNow: filgotinib rejection, delays in diagnosis, metformin benefits COVID, Abx and IBD, and UPA beats MTX.
Read Article
Canakinumab Tapering in Still's Disease
You can reduce - but not stop - canakinumab therapy in patients who are in complete clinical remission in children with systemic juvenile idiopathic arthritis.
Read Article
Peter Nash drpnash ( View Tweet)
New Criteria for Discoid Lupus
JAMA Dermatology has proposed an initial validation of classification criteria for discoid lupus erythematosus (DLE), primarily for research purposes, but with clinical applicatility.
Read Article
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Filgotinib Decision Delayed by FDA
On August 18th, Gilead and Galapagos received a complete response letter from the FDA, which will delay consideration of filgotinib for the treatment of moderate-to-severe RA.
Read Article
Links:
Dr. John Cush RheumNow ( View Tweet)